2024-10-26 - Analysis Report
## Abbott Laboratories (ABT) Stock Analysis Report

**Company Overview:** Abbott Laboratories is a global healthcare company that develops, manufactures, and sells a wide range of medical devices, pharmaceuticals, and nutrition products.

**Performance Analysis:**

**1. Relative Performance:**
* **Cumulative Return:** ABT: 108.65%, S&P 500 (VOO): 135.48%
* **Cumulative Return Difference:** -26.83%
* **Relative Outperformance:** 15.19% (meaning that ABT is currently underperforming the S&P 500 by 26.83%, which places it in the 15.19th percentile of its historical performance range)

**2. Recent Price Movements:**
* **Last Market Close:** 114.24
* **5-Day Moving Average:** 117.21
* **20-Day Moving Average:** 115.46
* **60-Day Moving Average:** 113.67

**3. Technical Indicators:**
* **RSI:** 63.5 (suggests that the stock is currently in overbought territory)
* **PPO:** 0.01 (indicating a weak momentum)
* **Delta_Previous_Relative_Divergence:** 3.96 (+) (positive divergence suggests a short-term upward trend)
* **Expected Return:** 0.0% (over a long-term period, at least two years, ABT is expected to deliver a 0.0% return relative to the S&P 500)

**4. Recent Earnings and Outlook:**

| Date      | EPS    | Revenue       |
|-----------|--------|---------------|
| 2024-07-31 | 0.74   | 10.38 B$      |
| 2024-05-02 | 0.70   | 9.96 B$      |
| 2023-11-01 | 0.82   | 10.14 B$      |
| 2023-08-03 | 0.79   | 9.98 B$      |
| 2024-07-31 | 0.79   | 9.98 B$      |

* **Latest Earnings (2024-07-31):** 0.74 EPS, 10.38 B$ revenue. (No analyst estimate available for comparison.)
* **Outlook:** Recent earnings indicate a steady growth in both EPS and revenue. However, the stock's underperformance against the S&P 500 raises concerns about potential growth headwinds. Further analysis of industry trends and competitor performance is necessary for a clearer outlook.

**5. News and Recent Issues:**

* **Recent Earnings News:** No significant news regarding ABT earnings was found in the past two days.
* **Recent Market Outlook:** Some analysts suggest that ABT's dividend yield and its focus on essential healthcare products could provide some insulation from market volatility. 
* **Analyst Opinions and Performance Highlights:** FINBOLD reports a consensus "Hold" rating for ABT. The recent acquisition of Alcon could positively impact future earnings, but investors should consider the regulatory risks associated with the deal.

**6. Comprehensive Analysis:**

ABT has been underperforming the S&P 500 in recent months, though its recent earnings indicate a positive trend. Technical indicators suggest overbought conditions and weak momentum, while the expected return relative to the S&P 500 is neutral. Although recent acquisition might positively affect future earnings, investors should be cautious about the regulatory risks. More research into industry trends, competitor analysis, and potential growth catalysts is required for a well-rounded assessment.

**7. Conclusion:**

While ABT has a long history of stability and dividend payouts, its recent underperformance against the S&P 500 and overbought technical conditions suggest a cautious approach for investors. Further research is necessary before considering any investment decisions.